Salud financiera de hoja de balance de Nexalin Technology

Salud financiera controles de criterios 6/6

Nexalin Technology tiene un patrimonio de los accionistas total de $2.3M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $2.8M y $507.2K respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$2.14m
Patrimonio	US$2.33m
Total pasivo	US$507.22k
Activos totales	US$2.83m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($2.6M) de NXL superan a sus pasivos a corto plazo ($507.2K).

Pasivo a largo plazo: NXL no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: NXL está libre de deudas.

Reducción de la deuda: NXL no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: NXL tiene suficiente cash runway para 8 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que NXL disponga de suficiente cash runway para 6 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Nexalin Technology

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Nexalin Technology, Inc. Provides Non-Compliance Update

Nexalin Technology, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Nexalin Technology Receives Written Notice from the Nasdaq Listing Qualifications Department Regarding Not Eligible for an Additional 180 Calendar Day Compliance Period

Nexalin Technology, Inc. Receives Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Recent updates

Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal

Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device

Nexalin Technology, Inc. has filed a Follow-on Equity Offering in the amount of $7 million.

Nexalin Technology, Inc. Provides Non-Compliance Update

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.10 loss in 1Q 2023)

Nexalin Technology, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Nexalin Technology, Inc. has filed a Follow-on Equity Offering in the amount of $5.646485 million.

Nexalin Technology Accelerates Manufacturing of Its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board

Full year 2023 earnings released: US$0.63 loss per share (vs US$0.30 loss in FY 2022)

Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Nexalin Technology, Inc. Announces Positive Results from Clinical Study of Its Gen-2 Tacs Device for Treating Adult Patients with Chronic Insomnia

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

Nexalin Technology, Inc. Unveils Gen-3 HALO™? Clarity 15 Milliamp Neurostimulation Device

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.026 loss in 3Q 2022)

Nexalin Technology Receives Written Notice from the Nasdaq Listing Qualifications Department Regarding Not Eligible for an Additional 180 Calendar Day Compliance Period

Nexalin Technology, Inc. Announces Publication of Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal

Nexalin Technology, Inc., Annual General Meeting, Nov 10, 2023

Nexalin Technology, Inc., Annual General Meeting, Nov 10, 2023

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.09 loss in 2Q 2022)

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of Its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

Nexalin Technology, Inc. Receives Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.08 loss in 1Q 2022)

Full year 2022 earnings released: US$0.30 loss per share (vs US$1.43 loss in FY 2021)

Nexalin Technology, Inc. Appoints Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

Insufficient new directors

Third quarter 2022 earnings released: US$0.026 loss per share (vs US$0.40 loss in 3Q 2021)

Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million.

Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million.

Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million.

Insufficient new directors

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera